Current issues in the management of nausea and vomiting

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

This state-of-the-art review describes the development, over the past 12 years, of new agents for the control of chemotherapy- and radiotherapy- induced emesis. While the mechanism of chemotherapy-induced nausea and vomiting is still not fully understood, significant progress in prevention of the symptoms has been achieved. The discovery that high-dose metoclopramide was very effective in antiemetic control ultimately led to the development of a new class of antiemetics, the 5-HT3 receptor antagonists, of which tropisetron is the most recent to be introduced. The emphasis of the review is on acute chemotherapy-induced emesis and includes current thinking on the influence of patient characteristics on the emetic outcome. The new 5-HT3 receptor antagonists do not demonstrate any of the distressing extrapyramidal reactions so frequently encountered with conventional antiemetics acting at dopamine receptor sites. Mild headache is the most characteristic side effect of this class of agents. The major advantages of the newer 5-HT3 receptor antagonists, such as tropisetron, over the conventional antiemetic regimens are convenience, flexibility and, above all, single-dose usage.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume4
Issue numberSUPPL. 3
StatePublished - 1993
Externally publishedYes

Fingerprint

tropisetron
Antiemetics
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Nausea
Vomiting
Drug Therapy
Emetics
Metoclopramide
Dopamine Receptors
Headache
Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Current issues in the management of nausea and vomiting. / Gralla, Richard J.

In: Annals of Oncology, Vol. 4, No. SUPPL. 3, 1993.

Research output: Contribution to journalArticle

@article{7faad0f4e69d45c5b6e59a45d07e8835,
title = "Current issues in the management of nausea and vomiting",
abstract = "This state-of-the-art review describes the development, over the past 12 years, of new agents for the control of chemotherapy- and radiotherapy- induced emesis. While the mechanism of chemotherapy-induced nausea and vomiting is still not fully understood, significant progress in prevention of the symptoms has been achieved. The discovery that high-dose metoclopramide was very effective in antiemetic control ultimately led to the development of a new class of antiemetics, the 5-HT3 receptor antagonists, of which tropisetron is the most recent to be introduced. The emphasis of the review is on acute chemotherapy-induced emesis and includes current thinking on the influence of patient characteristics on the emetic outcome. The new 5-HT3 receptor antagonists do not demonstrate any of the distressing extrapyramidal reactions so frequently encountered with conventional antiemetics acting at dopamine receptor sites. Mild headache is the most characteristic side effect of this class of agents. The major advantages of the newer 5-HT3 receptor antagonists, such as tropisetron, over the conventional antiemetic regimens are convenience, flexibility and, above all, single-dose usage.",
author = "Gralla, {Richard J.}",
year = "1993",
language = "English (US)",
volume = "4",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Current issues in the management of nausea and vomiting

AU - Gralla, Richard J.

PY - 1993

Y1 - 1993

N2 - This state-of-the-art review describes the development, over the past 12 years, of new agents for the control of chemotherapy- and radiotherapy- induced emesis. While the mechanism of chemotherapy-induced nausea and vomiting is still not fully understood, significant progress in prevention of the symptoms has been achieved. The discovery that high-dose metoclopramide was very effective in antiemetic control ultimately led to the development of a new class of antiemetics, the 5-HT3 receptor antagonists, of which tropisetron is the most recent to be introduced. The emphasis of the review is on acute chemotherapy-induced emesis and includes current thinking on the influence of patient characteristics on the emetic outcome. The new 5-HT3 receptor antagonists do not demonstrate any of the distressing extrapyramidal reactions so frequently encountered with conventional antiemetics acting at dopamine receptor sites. Mild headache is the most characteristic side effect of this class of agents. The major advantages of the newer 5-HT3 receptor antagonists, such as tropisetron, over the conventional antiemetic regimens are convenience, flexibility and, above all, single-dose usage.

AB - This state-of-the-art review describes the development, over the past 12 years, of new agents for the control of chemotherapy- and radiotherapy- induced emesis. While the mechanism of chemotherapy-induced nausea and vomiting is still not fully understood, significant progress in prevention of the symptoms has been achieved. The discovery that high-dose metoclopramide was very effective in antiemetic control ultimately led to the development of a new class of antiemetics, the 5-HT3 receptor antagonists, of which tropisetron is the most recent to be introduced. The emphasis of the review is on acute chemotherapy-induced emesis and includes current thinking on the influence of patient characteristics on the emetic outcome. The new 5-HT3 receptor antagonists do not demonstrate any of the distressing extrapyramidal reactions so frequently encountered with conventional antiemetics acting at dopamine receptor sites. Mild headache is the most characteristic side effect of this class of agents. The major advantages of the newer 5-HT3 receptor antagonists, such as tropisetron, over the conventional antiemetic regimens are convenience, flexibility and, above all, single-dose usage.

UR - http://www.scopus.com/inward/record.url?scp=0027220149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027220149&partnerID=8YFLogxK

M3 - Article

VL - 4

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 3

ER -